The aim of our study was to evaluate the impact of additional gene mutations and cytogenetic abnormalities on the prognosis of AML patients with NPM1 and/or FLT3-ITD mutations, receiving intensive chemotherapy. The gene discussed is FLT3; the disease is acute myeloid leukemia.